You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Helmet for Maintainer Head and Hearing Protection

    SBC: CREARE LLC            Topic: N04255

    Improved head and hearing protection is required for aircraft maintainers working on a carrier flight deck during launch and recovery operations. Legacy Flight Deck Cranials are inadequate in many aspects including hearing protection, impact protection, cleaning, comfort, and compatibility with night vision devices (NVDs) and with chemical, biological, and radiological (CBR) equipment. In this p ...

    SBIR Phase II 2008 Department of DefenseNavy
  3. Wide dynamic range x-ray Mixed-Mode Pixel Array Detector

    SBC: Sydor Instruments, LLC            Topic: 09a

    Synchrotron light sources and X-ray free electron lasers are now generating shorter pulses with more intense light than ever before possible. The capabilities of these new sources grant unprecedented access into the workings of the natural world. X-ray detectors, as they currently stand, cannot accommodate the large dynamic range of collected x-rays in modern scattering experiments. This capabilit ...

    SBIR Phase II 2018 Department of Energy
  4. Sleeping Beauty Engineered B Cells for Mucopolysaccharidosis

    SBC: IMMUSOFT CORP            Topic: 300

    Project Summary Mucopolysaccharidosis type IMPS Iis an autosomal recessive storage disease caused by the absence ofL iduronidaseIDUAresulting in systemic accumulation of glycosaminoglycanGAGstorage materialshepatosplenomegalyskeletal dysplasiascardiopulmonary obstructionprogressive neurologic impairment and death by ageMPS I is currently treated by enzyme replacement therapy and by allogeneic hema ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. New Platform Technologies for Viral and Therapeutic Evolution Assays

    SBC: AUTONOMOUS THERAPEUTICS INC            Topic: SB171003

    From HIV to metastatic cancer, state-of-the-art therapeutics are static biological or pharmaceutical compounds—whose efficacy is inevitably lost once their evolving disease targets sufficiently mutate. We engineered the first adaptive therapeutics designed to co-adapt with adapting disease agents—to provide ‘resistance-proof’ disease control. Known as Therapeutic Interfering Particles (‘ ...

    SBIR Phase II 2018 Department of DefenseDefense Advanced Research Projects Agency
  6. Minimally Invasive Cardiac Monitor for Neonatal and Pediatric ICU

    SBC: TRANSONIC SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Currently there exists no technology for routine measurement of cardiac output (CO) in neonates (0.4-2.5Kg) and low weight pediatric (2.5Kg+) patients in the intensive care unit (ICU). Accurate measurement of CO would a llow for better assessment of therapies and thereby improve patient health care. Conventional methods used with adults for routine CO measureme ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid Cystic Fibrosis Mutation Screening Test

    SBC: Pharmaseq, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to configure a DNA-based assay to detect mutations in the gene related to cystic fibrosis (CF), encoding the cystic fibrosis transmembrane conductance regulator protein (CFTR). The assay will have an extende

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease

    SBC: PRECYTE INC            Topic: NIA

    Project Summary. PreCyte is developing the Indicator Cell Assay Platform (iCAP) as a broadly applicable and inexpensive blood-based assay that can be used for the early detection of disease, disease stage stratification, prognosis and predicting response to therapy for a variety of diseases. The iCAP uses cultured, standardized cells as biosensors, capitalizing on the ability of cells to respond t ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Improved cleaning technology for reducing risk of transmitting infection in endoscopy.

    SBC: ADVANCED BIODEVICES LLC            Topic: R

    7. Project Summary/Abstract: Outbreaks of infection caused by contaminated endoscopes are a serious public health problem that has even resulted in patient deaths. Currently, because of the narrowness of the channels and complexity of the endoscope, there simply is no reliable way of achieving this. The existing cleaning protocols also are highly dependent on operator technique. Accordingly, this ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting leukocyte metabolism to treat human autoimmune disease

    SBC: Immunext, Inc.            Topic: R

    ImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient transporter SLC16A1 (MCT1) is a multi-pass transmembrane protein responsible for the facilitated transport of critical metabolites, including products of glycolysis: lactate, pyruvate and ketones. Our strong preliminary data support ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government